Skip to content

Paternal donor haploid hematopoietic stem cell transplantation for children with thalassemia major

Paternal donor haploid hematopoietic stem cell transplantation for children with thalassemia major

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300068997
Enrollment
Unknown
Registered
2023-03-03
Start date
2023-04-01
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thalasemia

Interventions

Experimental group:Paternal donor haploid hematopoietic stem cell transplantation
Control group:Patients' donors were HLA identical non consanguineous or sibling donors

Sponsors

Zhongshan Hospital Xiamen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Frequency of genetic diagnosis or blood transfusion (>4 times/year) is consistent with thalassemia major; 2. Aged 2-14 years, weight <40kg; 3. Receiving haploid hematopoietic stem cell transplantation from father as donor; 4. Receive sibling or non-related HLA fully compatible hematopoietic stem cell transplantation; 5. Volunteer to take the test, and the guardian signs the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with severe cardiac insufficiency and ejection fraction EF lower than 55%; Or severe arrhythmia, which the investigators evaluated as intolerant to preconditioning; 2. Patients with severe pulmonary insufficiency (obstructive and/or restrictive ventilation disorders) who could not tolerate preconditioning regimen as assessed by the investigators; 3. Patients with severe liver function impairment or liver fibrosis, liver function index (ALT) more than 3 times higher than the upper limit of normal value, who could not tolerate pretreatment regimen; 4. With severe renal insufficiency, renal function index (Cr) is more than 2 times the upper limit of normal value (ULN); Or creatinine clearance Ccr was less than 50ml/min, and the investigators evaluated that the patients could not tolerate the pretreatment regimen; 5. Serious infection existed before transplantation, and researchers evaluated patients who were difficult to control and unsuitable for transplantation.

Design outcomes

Primary

MeasureTime frame
Overall survial;Thalasemia-free survial;Implantation rate;Incidence of GVHD;

Secondary

MeasureTime frame
Complication profile;Viral reactivation rates;Transplant related mortality;

Countries

China

Contacts

Public ContactLu Quanyi

Zhongshan Hospital Xiamen University

quanyilu@Hotmail.com+86 136 0095 9425

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026